Trulieve Reports Fourth Quarter and Full-Year 2020 Results and Announces Full-Year 2021 Guidance
Builds on national expansion and achieves 12th consecutive quarters of profitability.
2020 Financial Highlights
- Exceeded guidance with another record quarter and third straight year of profitability.
- On a full-year basis, achieved revenues of
$521.5 million , representing year-over-year growth of 106%. Record fourth quarter revenues of$168.4 million , a 24% sequential increase. - Achieved, on a full-year basis, net income of
$63.0 million resulting in a full year earnings per share of$0.53 on a fully diluted basis. Absent the revaluation of our debt warrants, an impact of$42.7 million for the year, adjusted net income would have been$105.7 million resulting in earnings per share of$0.89 on a fully diluted basis. - 2020 Adjusted EBITDA of
$251.0 million , representing a year-over-year growth of 99%. Adjusted EBITDA of$78.2 million in the fourth quarter was an increase of 19% from the third quarter. - Delivered
$99.6 million in cash flows from operations for the year.
2020 Operational Highlights and Recent Events
- Announced that the
United States Securities and Exchange Commission declaredTrulieve's resale registration statement on Form S-1 effective onFebruary 4, 2021 , thereby makingTrulieve aU.S. reporting company. - Approved to start growing plants at our Tier 9 facility in
Holyoke by theCannabis Control Commission inMassachusetts . - Expanded national footprint in the Northeast with closings of the acquisition of Solevo Wellness, adding three operational dispensaries in
Pennsylvania , and PurePenn, a cultivator and processor supplying wholesale product to 100% of dispensary operations in the state. - Entered a 6th state with the award of a processor permit by the
West Virginia Office of Medical Cannabis and four dispensary permits subsequent to year-end. Announced a Definitive Agreement for the acquisition ofMountaineer Holding, LLC , aWest Virginia company that holds a cultivation permit and two dispensary permits, resulting in a vertical platform. - Opened 11 new retail dispensaries in the fourth quarter, ending the year with 75 stores in the U.S. Added over 200,000 square feet of cultivation facilities during 2020, ending the year with almost 2 million square feet of cultivation facilities, to support this explosive growth of new stores.
- Ended 2020 with a 49% market share in oil and 53% market share in flower in the state of
Florida and achieved record flower and oil sales during at the end of December, selling 93.7M mgs of oil and 36,330 ounces, or over one ton of flower. - Completed significant upgrade to infrastructure with the migration to an SAP S4 platform, which among other things will help support the Company's planned national hub model expansion.
- Led diversity, equity and inclusion activities throughout the country in both local and national programs including support for Minorities 4Medical Marijuana,
Last Prisoner Project , and CultivatED, and supported a number of programs including bootcamps, women's programs, expungement clinics and clemency efforts.
"2020 was a year of foundational growth that sets the stage for what we expect will be an exciting and transformational year of national expansion. We had an excellent fourth quarter with strong financial performance capping off our highest annual revenue, net income and Adjusted EBITDA year to date. Our results reflect the outstanding work we've accomplished as a company and our focus on continuous improvement. Our full-year Adjusted EBITDA in 2020 was nearly equal to our prior year revenue," stated
Rivers continued, "As we enter 2021 with the political changes and heightened focus on cannabis in the country, we believe these shifts along with our momentum and strategic vision position us for a strong year ahead. We remain committed to maintaining our leadership position in the southeast while continuing to build-out our hub strategy throughout the
Financial Highlights
GAAP |
|||||||||
Results of operations |
For the Three Months Ended, |
For the Three Months Ended |
For the Twelve Months Ended |
||||||
(Figures in millions and % change |
|
|
% |
2020 |
2019 |
% |
2020 |
2019 |
% |
Total Revenue |
|
|
24% |
|
|
111% |
|
|
106% |
Gross Profit |
|
|
17% |
|
|
85% |
|
|
101% |
Gross Profit % |
71% |
75% |
- |
71% |
81% |
- |
74% |
76% |
- |
Operating Expenses |
|
|
32% |
|
|
110% |
|
|
112% |
Operating Expenses % |
31% |
29% |
- |
31% |
31% |
- |
30% |
29% |
- |
Net income |
|
|
(83%) |
|
|
(75%) |
|
|
19% |
Adjusted EBITDA1 |
|
|
19% |
|
|
79% |
|
|
99% |
1 See "Non-GAAP Financial Measures" below for a reconciliation to GAAP. |
The Company's Annual Report on Form 10-K for the year ended
This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.
Financial Guidance
Guidance presented in millions
|
2020 Actual |
2021 |
Revenue |
|
|
Adjusted EBITDA1 |
|
|
1, See "Non-GAAP Financial Measures" below for a reconciliation to GAAP. |
The Company does not provide reconciliations of its annual non-GAAP Adjusted EBITDA guidance to GAAP net income because the Company is unable to estimate with reasonable certainty certain operational aspects without unreasonable effort. These items are uncertain, depend on various factors, and may have a material effect on the Company's results computed in accordance with GAAP. A reconciliation between the historical GAAP and non-GAAP financial measures presented in this release is provided at the end of this release.
Conference Call
The Company will host a conference call and live audio webcast on,
All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until
A live audio webcast of the conference call will be available at:
https://investors.trulieve.com/events-presentations
Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 90 days by clicking the link above.
About
Trulieve is primarily a vertically integrated "seed-to-sale" company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of
To learn more about Trulieve, visit www.Trulieve.com.
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP Adjusted EBITDA, for each of the periods presented:
GAAP Reconciliation |
|||||||||
Reconciliation of Non-GAAP |
For the Three Months Ended, |
For the Three Months |
For the Twelve Months |
||||||
(Figures in millions and % |
December |
September |
% |
2020 |
2019 |
% |
2020 |
2019 |
% |
Net Income (GAAP) |
$ 3.01 |
|
-83% |
$3.01 |
|
-75% |
$63.01 |
|
19% |
Add (Deduct) Impact of: |
|||||||||
Depreciation and Amortization |
|
|
20% |
|
|
186% |
|
|
148% |
Depreciation included in Cost of Goods Sold |
|
|
0% |
|
|
0% |
|
|
0% |
Interest Expense, Net |
|
|
-31% |
|
|
-12% |
|
|
124% |
Share-Based Compensation |
$ 0.6 |
|
7% |
|
$ - |
|
$ - |
||
Other Expense (Income), Net |
|
|
178% |
|
|
423% |
|
|
6602% |
Provision for Income Taxes |
|
|
5% |
|
|
66% |
|
|
87% |
Acquisition and Transaction Costs |
|
$ - |
|
$ - |
|
$ - |
|||
Inventory Step up, Fair Value |
|
$ - |
|
$ - |
|
$ - |
|||
Total Adjustments |
|
|
55% |
|
|
138% |
|
|
156% |
Adjusted EBITDA |
|
|
19% |
|
|
79% |
|
|
99% |
1. |
Excluding the revaluation of our debt warrants in the fourth quarter, an impact of |
Forward-Looking Statements
This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements relate to the Company's expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding the Company's expected financial performance for fiscal 2021, its plans for expansion, the scope and timing of adoption of cannabis in the
SOURCE